1. Record Foreign Investment Inflow

Foreign direct investment (FDI) in Anhui’s healthcare sector reached RMB 12.8 billion (approximately USD 1.77 billion) in the first half of 2026, representing a remarkable 40% increase over the same period in 2025. This marks the highest half-year FDI inflow into the province’s healthcare sector on record and positions 2026 to potentially surpass the full-year FDI record of RMB 18.5 billion set in 2023.

The data, compiled by the Anhui Department of Commerce’s Foreign Investment Administration, covers all foreign-invested enterprise registrations, capital increases in existing FIEs, and cross-border M&A transactions in healthcare-related industries. The figures exclude portfolio investments and short-term capital flows, focusing strictly on long-term productive investments.

A total of 47 new foreign-invested healthcare enterprises were established in Anhui during H1 2026, up from 34 in H1 2025. In addition, 22 existing FIEs in the healthcare sector executed capital expansion plans, increasing their registered capital by an aggregate RMB 4.3 billion. The average investment per new FIE rose from RMB 178 million in H1 2025 to RMB 224 million in H1 2026, indicating a trend toward larger, more substantial projects.

2. Major Deals and Investment Profiles

Several landmark deals drove the sharp increase in FDI inflows during H1 2026. These transactions span medical devices, biopharmaceuticals, healthcare services, and digital health, reflecting the breadth of foreign investor interest in Anhui’s healthcare ecosystem.

2.1 Siemens Healthineers — Diagnostic Imaging Manufacturing Campus (RMB 1.8 billion)

The largest single foreign healthcare investment in Anhui’s history, Siemens Healthineers broke ground on a RMB 1.8 billion diagnostic imaging manufacturing campus in the Hefei National High-Tech Industrial Development Zone in March 2026. The 150,000-square-meter facility will produce CT scanners, MRI systems, and ultrasound devices for both the Chinese domestic market and export to Asia-Pacific markets. The campus is expected to employ 2,500 workers when fully operational in 2028, including 600 R&D engineers. Siemens cited Anhui’s skilled workforce, logistics connectivity, and the new healthcare foreign investment guidelines as key factors in selecting Anhui over competing locations in Jiangsu and Shandong.

2.2 Novo Nordisk — Diabetes Care R&D Center (RMB 850 million)

The Danish pharmaceutical giant established its third China R&D center in Hefei, with a focus on diabetes care innovation and real-world evidence generation for the Chinese population. The center will employ 300 researchers and clinical scientists and will collaborate with Anhui Medical University and the First Affiliated Hospital of the University of Science and Technology of China on clinical trials. The project benefited from the newly launched Anhui Healthcare Innovation Fund, which co-invested RMB 200 million through its Tier 3 strategic co-investment track.

2.3 Medtronic — Minimally Invasive Surgery Device Plant (RMB 650 million)

Medtronic’s new manufacturing facility in Wuhu’s Medical Device Industrial Park will produce laparoscopic surgical instruments, robotic surgery accessories, and advanced wound closure products. The facility is Medtronic’s second China manufacturing base and is designed to serve as the company’s Asia-Pacific export hub for minimally invasive surgery products. Commercial production is expected to begin in Q3 2027.

2.4 Roche Diagnostics — IVD Reagent Manufacturing (RMB 520 million)

Roche Diagnostics expanded its existing Anhui operations with a new in-vitro diagnostics (IVD) reagent manufacturing line in Hefei. The expansion doubles Roche’s IVD production capacity in China and includes a dedicated R&D lab for adapting global assays to the Chinese market. The project was supported by Anhui’s fast-track approval process, with all permits secured within 45 working days.

2.5 ResMed — Respiratory Care Manufacturing (RMB 380 million)

Australian respiratory medical device company ResMed established its first China manufacturing facility in Bengbu, producing sleep apnea devices, ventilators, and respiratory masks for the Chinese and Southeast Asian markets. The company cited Anhui’s competitive labor costs and land prices, combined with improving logistics infrastructure, as decisive factors.

3. Sector Breakdown of FDI Inflows

Foreign investment in H1 2026 was distributed across healthcare sub-sectors in a pattern that reflects both Anhui’s strategic priorities and global investor interests.

3.1 Medical Device Manufacturing — 45% of Total FDI

Medical device manufacturing attracted RMB 5.76 billion in FDI, maintaining its position as the dominant healthcare investment category. Within this segment, diagnostic imaging equipment (34% of medical device FDI), surgical instruments and robotics (28%), cardiovascular devices (18%), and IVD equipment and reagents (12%) led the inflows. The dominance of medical device manufacturing reflects Anhui’s success in building a comprehensive supply chain ecosystem, with over 400 medical device companies now operating in the province.

3.2 Biopharmaceutical Manufacturing and R&D — 28% of Total FDI

Biopharmaceutical FDI reached RMB 3.58 billion, driven by Novo Nordisk’s R&D center and expansions at existing FIE pharmaceutical manufacturers. Notable sub-trends include a 64% increase in biosimilar manufacturing FDI and a 48% increase in CRO/CDMO-related investments. The biopharmaceutical category is growing as a share of total healthcare FDI, up from 22% in 2024 to 28% in H1 2026, suggesting a shift toward higher-value pharmaceutical investments.

3.3 Healthcare Services and Digital Health — 18% of Total FDI

FDI in healthcare services, including hospital management, telemedicine platforms, and healthcare IT services, reached RMB 2.3 billion. This segment grew 55% year-on-year, the fastest growth rate among all segments, reflecting the impact of the new guidelines permitting wholly foreign-owned hospitals and the launch of the telemedicine licensing category. Two foreign-invested hospital projects — an international general hospital in Hefei (RMB 600 million, US-invested) and a rehabilitation specialty hospital in Wuhu (RMB 280 million, Japanese-invested) — were approved under the new WFOE hospital framework.

3.4 TCM and Natural Products — 9% of Total FDI

FDI in TCM modernization and natural products reached RMB 1.15 billion, a 28% increase. These investments are primarily joint ventures between foreign companies and Anhui-based TCM enterprises, combining foreign expertise in quality control, packaging, and international distribution with local knowledge of herbal sourcing and traditional formulations.

4. Source Countries and Investor Profiles

The sources of healthcare FDI in Anhui have become increasingly diverse, with non-traditional investor countries growing in importance.

4.1 European Union — 38% of Total FDI (RMB 4.86 billion)

European investors, led by Germany (Siemens Healthineers, B. Braun), Denmark (Novo Nordisk), and France (Sanofi, bioMérieux), were the largest source of healthcare FDI in H1 2026. European companies have historically been the most active foreign investors in Anhui’s healthcare sector, and their continued commitment underscores confidence in the province’s investment environment. The EU-China investment agreement, while politically stalled, has not deterred European healthcare companies from committing significant capital to Anhui.

4.2 United States — 27% of Total FDI (RMB 3.46 billion)

US healthcare FDI was led by Medtronic, ResMed, and two large medical device contract manufacturers. US investors are particularly active in the medical device and digital health segments. The growth in US healthcare FDI in Anhui — up 36% year-on-year — is notable given the broader context of US-China trade tensions and suggests that healthcare investment decisions are being driven more by market opportunity than by geopolitical considerations.

4.3 Japan and South Korea — 15% of Total FDI (RMB 1.92 billion)

Japanese (Terumo, Olympus, Nipro) and South Korean (Samsung Medison, LG Life Sciences) investors contributed RMB 1.92 billion in healthcare FDI. Japanese investment is concentrated in medical devices and senior care technology, reflecting Japan’s expertise in these areas and the demographic similarities between Japan and Anhui’s aging population. South Korean investment is focused on diagnostic equipment and cosmetic medical devices.

4.4 ASEAN and Other Asian Markets — 12% of Total FDI (RMB 1.54 billion)

Singapore-based healthcare companies, including IHH Healthcare and Parkway Pantai, have shown increasing interest in Anhui’s hospital and healthcare services sector. Thai and Malaysian investors are active in TCM and natural products joint ventures. The growth in ASEAN-sourced FDI is expected to accelerate as RCEP benefits deepen economic integration.

4.5 Other Regions — 8% of Total FDI (RMB 1.02 billion)

Middle Eastern sovereign wealth funds, Australian healthcare companies (led by ResMed), and Canadian medical device firms round out the investor base. The participation of sovereign wealth funds — including Mubadala Investment Company (UAE) and the Qatar Investment Authority — in healthcare investment vehicles targeting Anhui is a new and notable development in H1 2026.

5. Key Drivers of Investment Growth

The 40% surge in healthcare FDI is attributable to multiple reinforcing factors, some structural and some specific to the 2025-2026 period.

5.1 Policy Liberalization

The new Healthcare Foreign Investment Guidelines released in early 2026 (covered in our article AH-IND-HEALTHCARE-NEWS-039) have been the single most important policy driver. The expanded list of permitted sub-sectors, reduced capital requirements, and — most critically — the opening of wholly foreign-owned hospital ownership in designated zones have unlocked investment projects that were previously deferred or directed to other provinces.

5.2 Infrastructure Improvements

Anhui’s logistics infrastructure has improved dramatically over the past three years. The expanded Hefei Xinqiao International Airport cargo terminal, the Anhui-Europe freight train service, and the upgraded Yangtze River port facilities in Wuhu and Ma’anshan have collectively reduced logistics costs for healthcare products by an estimated 15-20% compared to 2023 levels. These improvements are particularly important for medical device manufacturers that export a significant share of their production.

5.3 Talent Pool Development

The presence of 122 universities and colleges in Anhui, including the University of Science and Technology of China (USTC) and Anhui Medical University, has created a growing pool of healthcare-trained graduates. Anhui produces approximately 28,000 STEM graduates annually with healthcare-related degrees. The provincial government’s Talent Recruitment Program has also successfully attracted 1,200 overseas-trained Chinese healthcare professionals back to Anhui since 2022, including 380 with PhDs from top international universities.

5.4 Cost Competitiveness

Anhui’s operating costs remain substantially lower than those in China’s first-tier cities and coastal provinces. Average industrial land costs are 40-60% lower than in Shanghai or Suzhou. Manufacturing labor costs are 35-45% lower than in the Yangtze River Delta’s coastal cities. For foreign healthcare companies facing global cost pressures, these differentials translate into meaningful bottom-line improvements.

5.5 Demonstration Effect

The success of early-mover foreign investors in Anhui has created a demonstration effect that accelerates later-stage investment decisions. As Siemens Healthineers, Novo Nordisk, and Medtronic have publicly committed to their Anhui projects, other foreign healthcare companies have taken notice. The presence of an expanding cluster of world-class healthcare manufacturers in the province creates agglomeration benefits — shared suppliers, a specialized labor pool, and a supportive regulatory environment — that make Anhui progressively more attractive for each subsequent investor.

6. Investment Distribution Across Anhui’s Cities

The geographic distribution of healthcare FDI within Anhui reflects a shift toward a multi-cluster model, with investment spreading beyond the traditional dominance of Hefei.

Hefei remains the dominant destination for healthcare FDI, benefiting from its status as the provincial capital, the presence of USTC and Anhui Medical University, the Hefei National High-Tech Zone’s biomedical cluster, and the concentration of international airport and logistics infrastructure. However, second-tier cities are growing faster. Wuhu’s 55% growth was driven by Medtronic’s surgical device plant and expansions at several existing medical device manufacturers. Bengbu’s 68% growth, the highest in the province, was led by ResMed’s respiratory care facility and a new Japanese-invested IVD manufacturing plant.

For foreign investors considering Anhui, the choice of city should be guided by the specific requirements of the project. Medical device manufacturers and R&D-intensive projects benefit most from Hefei’s ecosystem. Pharmaceutical logistics and bulk API manufacturing may find better value in Ma’anshan’s port infrastructure. TCM-related investments naturally gravitate toward Bozhou’s world-class TCM market ecosystem. And investors seeking the most aggressive municipal-level incentives should evaluate Wuhu and Bengbu, where local governments have offered significant top-up incentives beyond the provincial baseline.

7. Economic Impact and Spillover Effects

The surge in healthcare FDI has generated significant economic spillover effects throughout Anhui’s economy.

Employment creation: The new foreign-invested healthcare projects announced in H1 2026 are expected to create 18,500 direct jobs over the next 2-3 years, with a further estimated 45,000 indirect jobs through supply chain and service economy multiplier effects. Average salaries in foreign-invested healthcare enterprises in Anhui are 35% higher than the provincial average for manufacturing jobs, contributing to rising household incomes and local consumption.

Technology transfer and skills upgrading: While mandatory technology transfer requirements have been eliminated, voluntary technology cooperation has flourished. The Siemens Healthineers campus includes a joint training center with USTC that will train 500 medical imaging engineers annually. Novo Nordisk’s R&D center includes a diabetes research fellowship program for Anhui Medical University graduates. These spillover effects enhance the quality of Anhui’s healthcare workforce and create a virtuous cycle that attracts further investment.

Supply chain development: The presence of major multinational healthcare manufacturers has catalyzed the development of a local supplier base. An estimated 120 new supplier companies have been established in Anhui since 2024 to serve foreign-invested healthcare manufacturers, covering areas such as precision metal parts, medical-grade plastics, sterile packaging, and specialized logistics services. Many of these supplier companies are themselves attracting foreign investment interest.

Real estate and infrastructure: The healthcare FDI boom has driven demand for commercial real estate, particularly industrial park space and office properties in Hefei’s biomedical cluster. Industrial property values in Hefei’s designated medical zones have appreciated 18% over the past 12 months, while remaining well below levels in Shanghai or Suzhou. The provincial government has accelerated infrastructure projects serving the medical zones, including new road connections, upgraded water treatment facilities, and expanded electricity grid capacity.

8. Frequently Asked Questions

9. Outlook for H2 2026 and Beyond

The outlook for foreign healthcare investment in Anhui remains strongly positive for H2 2026 and into 2027, though several factors warrant attention.

Pipeline strength: The Anhui Department of Commerce reports 34 healthcare FDI projects in advanced negotiation as of July 2026, with an aggregate potential investment value of approximately RMB 15 billion. If 50-60% of these projects are finalized, H2 2026 FDI could reach RMB 8-9 billion, bringing the full-year 2026 total to a projected RMB 20-22 billion — potentially exceeding the previous annual record of RMB 18.5 billion by 8-19%.

Policy continuity risk: The most significant risk to sustained FDI growth is policy continuity. The 2026 guidelines were issued by the current provincial administration, and any future change in provincial leadership or central government policy direction could alter the investment landscape. However, Anhui’s healthcare FDI policy enjoys broad cross-departmental consensus, and the provincial government has stated that the guidelines are part of a 10-year strategic plan that will be reviewed but not fundamentally altered before 2030.

Competing provinces: Anhui’s competitive advantages are being noticed by other provinces, some of which are developing their own healthcare FDI attraction strategies. Jiangxi and Henan have both signaled interest in adopting similar policy liberalization measures. Anhui will need to continue innovating to maintain its first-mover advantage in inland China healthcare FDI.

Global economic conditions: The FDI figures are, of course, subject to global macroeconomic conditions. A significant global recession, a sharp escalation in US-China trade tensions, or a sustained period of RMB appreciation could all dampen foreign investor appetite. However, the structural drivers of healthcare FDI in China — aging demographics, rising healthcare spending, and the ongoing modernization of China’s healthcare system — are secular trends that should continue to support investment regardless of cyclical economic fluctuations.

Overall, Anhui has established itself firmly on the map of China’s healthcare investment landscape. The 40% growth in healthcare FDI in H1 2026 is both a validation of the province’s policy strategy and a foundation for continued growth as Anhui builds toward its ambition of becoming a national healthcare innovation hub.